Nolvac

Quick links to important sections

Nolvac

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nolvac

What is Nolvac?

Nolvac is a pharmaceutical formulation containing the active ingredient tamoxifen. It belongs to a class of medications known as selective estrogen receptor modulators (SERMs). While it is often associated with the treatment of various stages of breast cancer, its mechanism of action allows it to be used in several clinical contexts related to hormone-sensitive conditions.

Mechanism of Action

The primary function of Nolvac is to interfere with the activity of estrogen, a hormone that can promote the growth of certain types of cells. In the breast, tamoxifen acts as an estrogen antagonist, meaning it binds to estrogen receptors in cells and prevents the hormone from attaching to them. This blockade inhibits the signals that would otherwise tell these cells to divide and grow.

Interestingly, Nolvac does not block estrogen in all parts of the body. In other tissues, such as the bones and the liver, it can act as an estrogen agonist, meaning it mimics some of the beneficial effects of estrogen, such as helping to maintain bone density.

Primary Uses

Nolvac is primarily utilized in the management of hormone receptor-positive breast cancer. This includes:

  • Adjuvant Therapy: Used following primary treatments like surgery or radiation to reduce the risk of the condition returning.
  • Metastatic Disease: Used to manage hormone-responsive breast cancer that has spread to other parts of the body.
  • Risk Reduction: In specific cases, it may be used to lower the probability of developing breast cancer in individuals who are at a higher clinical risk.
  • Ductal Carcinoma in Situ (DCIS): Used after surgery for DCIS to reduce the risk of invasive cancer developing.

Clinical Role

Because Nolvac targets the hormonal pathways that drive cell proliferation, it is a foundational component of endocrine therapy. Unlike chemotherapy, which targets all rapidly dividing cells, Nolvac specifically addresses the hormonal environment that supports the growth of receptor-positive cells. It is typically used as a long-term maintenance therapy to ensure sustained suppression of estrogen-driven activity.

Regulatory References

  1. NIH StatPearls: Amlodipine
  2. MedlinePlus Drug Information: Amlodipine

What side effects are possible with Nolvac?

Possible Side Effects and Safety Information

The official safety profile for Nolvac (Amlodipine) is structured around adverse reactions classified by frequency and the body system affected, as documented by regulatory agencies. The most frequently reported effects are consistent with its action as a peripheral arterial vasodilator.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized by their reported likelihood based on clinical data:

  • Very Common (Affects 1 in 10 or more): The most frequently documented effect is peripheral edema (swelling, typically of the ankles), aligning with Vascular Disorders.
  • Common (Affects up to 1 in 10): Effects include headache, dizziness, somnolence (drowsiness), palpitations, flushing, nausea, and fatigue.
  • Very Rare (Affects up to 1 in 10,000): These include rare but serious events such as allergic reactions, myocardial infarction (heart attack), hepatitis, jaundice, and severe skin reactions like Stevens-Johnson syndrome.

Documented Safety Considerations

Certain high-level safety constraints are noted in official labeling. Caution is advised regarding the potential for symptomatic hypotension (low blood pressure), particularly in patients with severe aortic stenosis. Regarding time-related patterns, headache, dizziness, and somnolence are reported as being more common at the beginning of treatment.

Serious Adverse Reactions officially documented include the very rare occurrence of worsening angina and acute myocardial infarction following treatment initiation or dose increase, especially in individuals with severe obstructive coronary artery disease.

Population-Specific Notes

Regulatory documents include specific considerations for certain patient groups. Individuals with hepatic impairment (liver issues) are noted to have decreased drug clearance. For older adults, a lower initial dose may be considered due to the potential for decreased physiological function. Use in patients with congestive heart failure has been associated with increased reports of pulmonary edema in some studies.

Overdose and Emergency Response

The official regulatory profile for Nolvac overdose is centered on the risks associated with the drug's potent vasodilatory action. Immediate medical attention must be sought if massive overdose is suspected or if manifestations of severe hypotension occur.

Documented Overdose Manifestations Required Emergency Actions
Excessive peripheral vasodilation Initiate active cardiac and respiratory monitoring.
Marked hypotension (severe low blood pressure) Provide cardiovascular support if hypotension occurs.
Possible reflex tachycardia Frequent blood pressure measurements are essential.

Severe Outcomes and Supportive Management

Overdosage is expected to cause marked hypotension requiring aggressive supportive intervention. The official regulatory documents state that no specific antidote is documented; consequently, management is focused on supportive measures. These measures include elevation of the extremities and the judicious administration of fluids to counteract hypotension.

If severe hypotension remains unresponsive to these conservative measures, the administration of vasopressors may be considered, while maintaining continuous attention to the patient’s circulating volume. The regulatory data notes that experience with intentional overdosage in human populations is limited.

Therapeutic Uses of Nolvac

Nolvac (tamoxifen) is a medicine that is commonly used across therapeutic domains involving certain distressing symptoms associated with hormone-sensitive conditions. The drug is relevant for easing symptoms linked to organ-specific functional stress in contexts involving heightened systemic burden. The medication is utilized for several key indications.

It is applied in addressing symptomatic areas of both early and advanced breast cancer in women and men, commonly used across conditions presenting with acute episodes. The drug is also relevant for managing symptoms that interfere with daily comfort when prescribed to help address the risk of developing invasive breast cancer in women diagnosed with ductal carcinoma in situ (DCIS) following surgery and radiation. Furthermore, it may assist with supportive management to help address the risk of getting breast cancer in high-risk women. In situations involving certain distressing symptoms, this medicine supports general well-being during symptomatic phases and provides support that helps ease the overall symptom burden.

“Tamoxifen may be part of symptomatic management in situations where patients experience recurrent or episodic manifestations of hormone-sensitive conditions.”

Quick Fact: Relief for Symptom Clusters (Nolvac supports patients during episodes of heightened discomfort by managing symptom clusters that may become intense or disruptive).

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nolvac (Tamoxifen) — Official Regulatory Information

The eligibility profile for Nolvac is defined by official governmental regulatory documents, establishing clear limitations based on patient status and medical history.

Eligibility Scope Status as Defined in Regulatory Labeling
Populations Allowed Adult females and males diagnosed with breast cancer.
Contraindicated Populations Pregnancy and Lactation; Known hypersensitivity to tamoxifen or excipients.
Age-Related Rules Contraindicated in children and adolescents; safety and efficacy are not established in this group.
Conditional Use Restrictions Women of childbearing potential must use adequate non-hormonal contraception during treatment and for a period after cessation.

Condition-Specific Eligibility Rules

Nolvac use is prohibited for patients with a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), or those requiring coumarin-type anticoagulant therapy (e.g., warfarin), when the medicine is prescribed for breast cancer risk reduction (e.g., Ductal Carcinoma In Situ). For patients with hepatic or renal impairment, the effects on the drug’s metabolism have not been determined in official studies, classifying use in these populations as non-established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Nolvac, which contains the active ingredient paracetamol (acetaminophen), requires careful consideration regarding co-administration with several other medicinal products and substance categories.

Clinically Significant Interacting Agents

Category Specific Medicines (Examples) Interaction Implication
Other Paracetamol-Containing Products Multivitamin/Mineral Supplements, Cold & Flu Medicines Greatly increases the risk of inadvertent paracetamol overdose and associated toxicity. Co-administration is strictly restricted.
Oral Anticoagulants Warfarin Regular, prolonged use may enhance the anticoagulant effect, increasing the risk of bleeding. The official guidance notes that occasional use has no clinically significant effect.
Gastrointestinal Motility Regulators Metoclopramide, Domperidone May accelerate the absorption of Nolvac.
Cholestyramine May reduce the absorption of Nolvac; an official spacing requirement of at least one hour is advised between administrations.
Hepatic Enzyme Inducers Carbamazepine, Phenytoin, Rifampicin Concomitant use with these agents can increase the potential risk of liver damage if Nolvac is ingested at high or toxic doses.
Specific Antibiotics Flucloxacillin Concomitant use, especially in patients with pre-existing risk factors (e.g., severe renal impairment), may lead to high anion gap metabolic acidosis (pyroglutamic acidosis).

This interaction structure outlines key constraints for safe use and reflects the standardized regulatory warnings published in official governmental documents for the active ingredient.

Mechanism of Action

How Nolvac Works: Mechanism of Action

Targeting Arterial Smooth Muscle Channels

Amlodipine mediates its primary mechanism of action via selective blockade of the L-type voltage-gated calcium channels found in the walls of the peripheral arteries. This action is a non-competitive inhibition that prevents the necessary influx of calcium ions into the arterial smooth muscle cells.


Modulating Systemic Vascular Resistance

By inhibiting the calcium influx, the drug interrupts the excitation-contraction coupling pathway, causing the arterial smooth muscle to relax and widen (vasodilation). This widespread relaxation reduces the Total Peripheral Resistance (TPR), which results in decreased pressure load (afterload) imposed on the cardiac muscle during systolic ejection.


Coronary Artery Dilation

The same mechanism causes the dilation of coronary arteries, which results in increased localized blood flow and oxygen availability to the myocardium. The action is confined to vascular smooth muscle contractility; it does not directly modulate major neurohormonal systems, such as the RAAS, or affect venous capacitance vessels.

Dosage and Administration Information

How to Use Nolvac

Nolvac is administered orally and is consistently taken once daily as a continuous regimen for long-term use. The medication should be taken at approximately the same time each day to maintain consistent blood levels, regardless of whether it is taken with or without food. If using an oral liquid or suspension form, the product must be shaken well before the required dose is measured and administered.

For most adults, the standard initial dose is 5 mg once daily, with the dose adjusted based on individual response, up to a maximum recommended dose of 10 mg once daily. Dosage adjustments, or titration, should generally occur at cautious intervals of 7 to 14 days to ensure the full effect of each dosage level is assessed before proceeding.

Population Group Labeled Starting Dose Maximum Daily Dose
Standard Adult 5 mg once daily 10 mg once daily
Older Adults/Hepatic Impairment Lower dose of 2.5 mg once daily is advised 10 mg once daily
Pediatric (Ages 6–17 for hypertension) 2.5 mg once daily 5 mg once daily

In the event of a missed dose, standard protocols suggest taking the forgotten dose as soon as it is remembered. If, however, it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. Double doses should never be taken to compensate for a missed one. No dose change is typically necessary for patients with renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nolvac

This overview summarizes the official clinical research and regulatory findings related to the evaluation of Nolvac (Amlodipine), focusing on the types of studies conducted, the outcomes monitored, and where the evidence remains limited or uncertain. This section provides context but not individual predictions or clinical recommendations.

Evidence for use in High Blood Pressure (Hypertension)

The research base for Nolvac in the study of high blood pressure is primarily built on large-scale, long-term Randomized Controlled Trials (RCTs) and systematic meta-analyses. Researchers extensively examined changes in both the upper and lower numbers of blood pressure readings (SBP/DBP) over the short term. Longer-duration studies investigated the occurrence of specific cardiovascular events, including stroke and heart attack. Findings describe patterns observed in the studies related to a change in both blood pressure readings and data concerning major cardiovascular events over the study period.

Evidence for use in Angina and Coronary Artery Disease

Nolvac was evaluated in research exploring its effect on certain types of chest discomfort known as angina. The research explored short-term symptom changes using functional measures, such as monitoring the reported frequency of anginal episodes and the measured duration of exercise time. In patients with angiographically documented coronary artery disease (CAD), long-term outcome studies focused on whether use of the medicine was associated with the frequency of needing a coronary revascularization procedure or hospitalization for angina.

Long-Term Studies and Follow-Up Data

Long-term follow-up data for Nolvac were crucial in the context of high blood pressure and CAD. Many of the major RCTs had median observation periods spanning several years. These trials aimed to capture whether any reported change in blood pressure was associated with long-term patterns related to major cardiovascular events over time. The available evidence, particularly from the largest comparative trials, describes the long-term patterns observed in groups of people with similar baseline characteristics.

Evidence in Special Populations

Research has examined the use of Nolvac in several specific groups. For older adults, studies report patterns where lower starting doses were often used, as researchers monitored changes in this group due to potentially decreased hepatic function. For pediatric patients (ages 6 to 17) with high blood pressure, research has monitored the measured change in blood pressure readings, but regulatory review notes that doses exceeding 5 mg per day have not been studied in this specific age range, and data for higher doses are limited.

What is Still Uncertain About Nolvac's Research

Research exploring Nolvac in patients with severe chronic heart failure is one area where the findings were mixed. Two large-scale RCTs were conducted for this condition; while one trial described patterns in a subgroup, a later trial reported inconsistent findings for the overall population. The certainty remains low for this specific clinical situation. More generally, some follow-up durations were limited for certain angina outcomes, and comparative evidence is limited against all newer therapeutic options for specific conditions. The results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Nolvac (FAQ)


Q: How long does it typically take for Nolvac to start working?

Official regulatory documents state that the highest concentration of the medicine in the blood is typically reached between 6 and 12 hours after an oral dose. The way the active ingredient works on the body's calcium channels leads to a gradual onset of its therapeutic effect.


Q: What is the usual duration of Nolvac's effect after taking it?

Studies indicate that the medicine has a long duration of action, with its half-life typically ranging from 30 to 50 hours. This prolonged duration supports the maintenance of antihypertensive effectiveness for a full 24 hours with chronic, once-daily administration.


Q: Will taking Nolvac make me feel tired or drowsy?

Regulatory product information states that feeling tired (fatigue) is a common side effect, affecting up to 1 in 10 people. Drowsiness or extreme sleepiness (somnolence) is also listed among the frequently reported adverse events in clinical data.


Q: Is it necessary to avoid specific foods or drinks while using Nolvac?

Official guidance advises avoiding the consumption of grapefruit and grapefruit juice. This is because they may potentially increase the level of the active ingredient in the blood, potentially leading to an unpredictable increase in the medicine’s blood pressure lowering effect.


Q: Do studies support Nolvac's use in patients who have tried other similar treatments?

Research supporting the use of the medicine has included trials where it was administered to patients who were already receiving other types of medication for their condition. These combinations, such as with diuretics, digoxin, or ACE inhibitors, are detailed in the clinical trial summaries.


Q: What is the general consensus on Nolvac's long-term effectiveness?

Official regulatory sources indicate that the blood pressure lowering effects are maintained with chronic, once-daily administration. Studies have specifically noted that tolerance to the medicine's effects was not demonstrated in patients who were studied for periods of up to one year.


Q: If I feel better, is it okay to stop taking Nolvac?

Patient information leaflets note the importance of continuing to take the medicine as prescribed, even if you begin to feel better. The decision to change or discontinue treatment is a clinical matter that must be reviewed with a healthcare professional.


Q: Are there any documented cases of Nolvac causing mood changes?

Regulatory data indicates that mood changes, including anxiety and depression, are listed as uncommon side effects. These effects are reported to affect up to 1 in 100 people.


Q: If Nolvac is taken at night, will it cause nighttime restlessness?

Difficulty sleeping, known as insomnia, is listed in official documentation as an uncommon adverse reaction. This means it is reported to affect up to 1 in every 100 people who use the medicine.


Q: Why is Nolvac not recommended for children?

Official regulatory summaries state that the medicine is not recommended for children younger than 6 years old. This is because the safety and effectiveness have not been established through research in that specific age group.


Q: Is Nolvac known to cause hair loss?

Hair loss (alopecia) is listed in official adverse event reports as a very uncommon side effect. This means it is reported to affect up to 1 in every 1,000 people.


Q: Do patients commonly report feeling nervous or anxious when starting Nolvac?

Nervousness is listed as a reported adverse event in official documentation. Furthermore, anxiety is specifically listed under uncommon side effects related to mood changes.


Q: Can Nolvac be used by people with a history of kidney issues?

Regulatory documents note that the way the body handles the active ingredient is generally not significantly affected by renal impairment (kidney issues). Regulatory information reports that the need for dosage adjustment is not typically indicated for patients with renal impairment.


Q: What are the most common reasons a doctor might tell a patient not to take Nolvac?

Official labeling includes warnings regarding the potential for symptomatic low blood pressure and the risk of worsening angina or heart attack upon starting treatment in individuals with severe coronary artery disease. Official warnings note specific caution regarding administration to patients with severe liver impairment.


Q: Is Nolvac considered a treatment or a medication that helps manage a condition?

The active ingredient is formally indicated for the treatment of hypertension (to lower blood pressure) and for the treatment of chronic stable angina and coronary artery disease. It is a prescription medication used to manage these conditions.


Q: Is Nolvac the same type of medicine as [similar drug name]?

Nolvac is classified as a dihydropyridine calcium channel blocker. It is noted for its high selectivity for vascular smooth muscle and its long elimination half-life, which supports its use as a once-daily medicine.


Q: Can Nolvac affect my ability to drive or operate machinery?

The medicine may affect coordination, reaction time, or judgment due to side effects like dizziness and somnolence. Official patient information reports that the medicine may affect coordination, and advises that patients should be aware of how the medicine affects them before driving or operating machinery.


Q: Is Nolvac considered safe for older adults (seniors)?

The active ingredient has been evaluated in older adults. Regulatory documents note that because of the potential for changes in how the body clears the medicine in older adults, a lower initial starting dose has been studied and is often referenced for this population.


Q: Are there any known issues with Nolvac and liver function?

The active ingredient is metabolized extensively by the liver. Official regulatory documents report that slow and careful dose adjustment has been recommended when administering the medicine to patients with severe liver impairment, due to the prolonged presence of the medicine in this population.


Q: Is Nolvac used for anything besides its main listed purpose?

The official indications listed in the regulatory labeling are the treatment of high blood pressure (hypertension) and the treatment of various forms of angina (chest pain) and documented coronary artery disease.


Q: Does Nolvac affect fertility?

Regulatory summaries indicate that animal studies have shown adverse effects on male fertility. Furthermore, reversible biochemical changes in sperm have been reported in some patients treated with this class of medication.


Q: Can Nolvac be divided or crushed if swallowing is difficult?

The patient information leaflet for the tablets notes that the tablet can be divided into equal doses. This is typically a descriptive fact related to the physical product.


Q: What kind of monitoring is typically required when a patient is on Nolvac?

Regular monitoring of blood pressure is typically required to determine the medicine's effectiveness. Adjustments to the dosage, if needed, are generally made at cautious intervals, such as every 7 to 14 days.


Q: Is Nolvac a controlled substance?

The active ingredient is classified as a prescription-only medicine (Rx). Official classification indicates that this medicine is not listed as a controlled substance and belongs to the antianginal and calcium channel blocker classes.


Q: Does Nolvac have to be taken indefinitely?

The medicine is intended for chronic once-daily oral administration for its indicated conditions. The research evidence suggests that the therapeutic effects are maintained with long-term use. The determination of treatment duration is a matter of clinical judgment based on the individual's response and needs.


Q: What is the difference between Nolvac and a generic version of the drug?

Generic versions of the medicine contain the exact same active ingredient (Amlodipine) and must meet regulatory standards for the same strength and efficacy as the brand-name product. Differences are typically limited to the inactive ingredients or the cost.

How should Nolvac be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documentation for Nolvadex (tamoxifen citrate) mandates specific storage conditions to maintain product stability.

Requirement Stated Condition
Temperature Limit Store at a temperature that does not exceed 30 C.
Environmental Protection Must be protected from light and moisture.
Packaging Rule Keep the tablets in their original, tightly closed container.

To ensure safety, the medicine must be stored out of the sight and reach of children.

For disposal, the product is classified as a Hazardous Drug, meaning waste must not be poured down drains or sewers. While the SmPC states no special disposal requirements for unused product, if no take-back program is available, disposal should follow local guidelines for hazardous chemical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nolvac found in:

A-Z Index: